To analyze the activity of the CDllc promoter during myeloid differentiation without the limitations of transient expression systems, we have stably transfected the myeloid U937 cell line with the pCDllC36l-Luc plasmid, in which the expression of the firefly luciferase cDNA is driven by the CDllc promoter region -361/+43, previously shown to confer myeloid specificity to reporter genes. The stable transfectants (U937-C361) retained the a b i l i t o differentiate in response to phorbol-ester (PMA), sodium butyrate (SB), granulocyte-macrophage colony-stimulating factor (GM-CSF), and other differentiating agents. U9374361 differentiation correlated with increased cellular luciferase levels, showing the inducibility of the CD1 l e promoter during myeloid differentiation and establishing the U937-C361 cells as a suitable system for studying the myeloid differentiationinducing capacity of cytokines, growth factors, and other biological response modifiers. Unexpectedly, the inducibility of the CDllc gene promoter showed distinct kinetics and URING MYELOID DIFFEFWNTIATION, hematopoietic stem cells become committed to myeloid precursors that later differentiate into fully functional end-stage cells, a process which is accompanied by the coordinate expression and repression of numerous genes.' Myeloid leukemic cells are arrested at distinct stages of the differentiation pathway, and a number of myeloid leukemic cell lines have been established that can be induced to acquire a more mature phenotype and, therefore, have been used to study the expression of myeloid differentiation-regulated genes.' The potential therapeutic implications of differentiation-inducing agents have been underscored by the successful application of the differentiation therapy in patients with acute promyelocytic leukemia. ' Myeloid cell adhesion and differentiation are closely interregulated processes. Although adhesion to extracellular matrix components and neighboring cells is required for the proper completion of the cellular differentiation p r~g r a m ,~ the pattern of expression of adhesion receptors greatly changes during myeloid differentiation? Most cell-adhesive interactions are mediated by Integrins, a family of cell surface heterodimeric glycoproteins involved in both intercellular adhesion and in cell-extracellular matrix interactions. The members of the 0 2 integrin subfamily, ie, lymphocyte function-associated antigen-l (LFA-l), Mac-l, and p150,95 (CD1 la-c/CD18), which play a key role in myeloid cell/ endothelium interactions during immune and inflammatory reactions: are leukocyte-specific. LFA-1 is expressed on all leukocytes, whereas Mac-l and p150,95 are almost exclu- U937 cells, a histiocytic lymphoma line with monoblastlike characteristics, can be induced to differentiate towards morphologically mature macrophage-like cells after treatment with agents such as phorbol myristate acetate (PMA),'.I3 granulocyte-macrophage colony-stimulating factor (GM-CSF),73'4 or sodium butyrate (SB).I5 To define the molecular basis for the p150,95 integrin induction during myeloid differentiation, U937 cells were stably transfected with a CD1 IC promoter-based reporter gene construct (U937-C361) and were used to characterize the activity of 
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myeloid cell lines HL-60 and U937, because of transcriptional mechanisms acting on their respective a-subunit genes.' The characterization of the CD1 lb'"'' and CD1 1c" gene promoter regions has shown their involvement in the tissue-specific expression of Mac-l and p150,95'0"2 and has shown the presence of initiator (Inr) sequences at their respective transcriptional start sites.'&'' U937 cells, a histiocytic lymphoma line with monoblastlike characteristics, can be induced to differentiate towards morphologically mature macrophage-like cells after treatment with agents such as phorbol myristate acetate (PMA),'.I3 granulocyte-macrophage colony-stimulating factor (GM-CSF),73'4 or sodium butyrate (SB).I5 To define the molecular basis for the p150,95 integrin induction during myeloid differentiation, U937 cells were stably transfected with a CD1 IC promoter-based reporter gene construct (U937-C361) and were used to characterize the activity of 3716 RUB10 ET AL the CD1 IC gene promoter in response to differentiation-triggering agents. Our results point out the usefulness of the derived U937-C361 cell line in determining the differentiation-inducing ability of other growth factors, cytokines, and biological response modifiers, show the inducibility of the CD1 IC gene promoter during the PMA-, SB-, or GM-CSFstimulated myeloid differentiation, and identify DNA sequence elements that confer the differentiation-inducibility to the CD1 IC promoter.
MATERIALS AND METHODS
Cell culture and transfection. U937 cells were grown in RPMI supplemented with 5% fetal calf serum, 2 mmol/L glutamine, and 50 pg/mL gentamicin (complete medium), at 37°C in a humidified atmosphere with 5% CO,. For stable transfectants, U937 cells (1 to 2 X lo7) were electroporated (100 V, 2,950 microfarads, 186 CL) in 500 pL RPMI containing 40 pg of BamHI-linearized pCDllC361-Luc and 10 pg of BamHI-linearized pSV2-ne0.".'~ After transfection, cells were suspended in complete medium, cultured for 48 hours, and maintained in complete medium supplemented with G418 (1.5 mg/mL). Once cell growth was evident, cells were harvested, and the (3418-selected population (U937-C361) was subjected to cloning by limiting dilution. For induction of differentiation, U937 or U937C-361 cells were resuspended in fresh complete medium ( S X IO'/mL), cultured for 9/12 hours and then treated with PMA (10 ng/mL), l-oleoyl-2-acetyl-glycerol (OAG; 20 pg/mL), GM-CSF (100 U/mL), 1,25 dihydroxyvitamin D3 (IO-* mol/L; kindly provided by Dr M. Uskokovic, Hoffmann-La Roche), dimethyl sulfoxide (DMSO; 1.4%), y-interferon (200 UlmL), etoposide (VP-16, 2 X mom), amacrine (AMSA; 10" mol/L), or SB (1 mmol/L) for up to 5 days. At the indicated time points, cells were harvested, washed, counted, and lysed. Unless otherwise indicated, luciferase determination was usually performed on lo5 cells from each culture condition using a Berthold Lumat LB 9501 luminometer, as described," and measuring light emission for 20 seconds. Output was quantitated as relative light units (RLU).
The deletion mutants from the CD1 I C promoter pCDllC361-Luc, pCDl 1C253-Luc, and pCDl lC160-Luc, containing the regions -361/+43, -253/+43, or -160/+43, respectively, have been previously described." Additional deletion constructs pCD 1 lC99-Luc, pCDl lC61-Luc, and pCDl IC53-Luc. including the regions -99/ +43, -61/+43, and -53/+43, were constructed after polymerase chain reaction (PCR) amplification of the corresponding fragments and ligation into the pXP2 plasmid. Site-directed mutagenesis of the Spl-70 site into a non-Spl-binding sequence was performed by standard proceduresL7 and will be described elsewhere (C. L6pez-Rodriguez, A.L. Corbi, manuscript submitted). The reporter plasmid containing a mutation at Spl-70 was termed pCDllC160(-70MUT)-Luc. The pCDl IC361(-85MUT)-Luc plasmid, was derived from pCDllC361-Luc after mutation of the Myb-binding site at -85 by site-directed m~tagenesis'~ using an oligouncleotide later used for electrophoretic mobility shift assay (EMSA) studies (mBoxD, see below). pCDllC160(-85)-Luc was constructed by PCR on pCDl lc361(-85)-Luc, using oligonucleotides (-160) 5'-CTT-GGATCCAAGCCAAGTCATCTGATGAGAG -3' (-138) (sense, CD1 I C pXP2 -160) and (+43) 5'-GATCTCGAGCTCCTG-GGCCG-3' (+28) (antisense, CD1 I C pXP2 +43) as PCR primers to amplify the whole CD1 IC promoter-derived insert and using further cloning into pXP2. The pXP2-derived pCDl1 A100-Luc plasmid, in which the expression of the luciferase cDNA is driven by the -100/ +83 fragment from the CD1 la promoter," was used as additional control in some experiments. All mutations and constructs were confirmed by sequencing and were electroporated in U937 cells, as described.'' After transfection, cells were split into 4 aliquots and either were left unueated or were cultured in the presence of PMA, GM-CSF, or SB. Fourteen hours after transfection, luciferase activities were determined. For comparative purposes, the "Promoter Activity Induction" of the differentiating agents on each construct was defined as the ratio of RLU in treated transfected cells to RLU in untreated transfected cells, after background subtraction and normalizing for cell number in each culture condition. A similar calculation was used to determine the effect of the differentiation-inducing agents on the luciferase activity in U937-C361 cells. When necessary, transfection efficiencies were normalized by including 20 pg of the pSVpgal plasmid in the electroporation mixture, and luciferase activities were determined on cell extracts containing identical pgalactosidase activity. In all cases, at least two distinct plasmid preparations of each deletion construct were tested by transfection.
Immunojuorescence analysis. U937 cells or U937-C361 transfectants were subjected to treatment with differentiation agents as indicated, harvested, washed in ice-cold phosphate-buffered saline, and resuspended in 100 pL of the following hybridoma culture supernatants: Bear-l (anti-CD1 Ib), HClll (anti-CDIlc), and TSI/ 18 (anti- CD1 8) . After washing, bound antibodies were detected using fluorescein-conjugated F(ab'), rabbit antimouse Ig, and cells were analyzed on a FACScan cytofluorometer. All incubations were performed in the presence of 1 % human AB serum to prevent binding through the Fc portion of the antibodies. The supernatant from the myeloma P3X63 was included as negative control.
Southern and Northern blot. Genomic DNA was isolated from the selected U937-C361 clones, and 10-1.18 aliquots were digested with EcoRI and BamHI. After electrophoresis and transfer onto nylon membranes using 1OX saline sodium citrate (SSC), filters were prehybridized and hybridized as described," using a 616-bp Xho IEcoRI fragment from the luciferase cDNA and a 404-bp BamHIXho I fragment from the CDllc promoter as probes. Both DNA fragments are contiguous in the pCDllC361-Luc plasmid used to establish the stable transfectants." Membranes were sequentially washed in 2X SSC and 0.5% sodium dodecyl sulfate at room temperature (for 45 minutes) and in 0.3X SSC and 0.5% sodium dodecyl sulfate at 37°C (for 15 minutes) and 65°C (10 minutes), and were exposed at -70°C with an intensifying screen. Northern blot was performed on total RNA isolated from untreated and PMA-, GM-CSF-, or SB-treated U937-C361 cells? using a 0.8-kb Pst I fragment from the CD1 I C cDNA, a 1.2-kb EcoRI-Hind111 fragment from the c-my cDNA, and a I-kb Pst I fragment from the P-actin cDNA,' as probes.
EMSA. A total of 50 ng of the CD1 IC promoter-based doublestranded oligonucleotides BoxD, mBoxD, or 2xMyb oligo'" were labeled using avian myeloblastosis virus (AMV) reverse transcriptase (7 U) and 50 pCi of either 32P-deoxyguanosine triphosphate or 3'P-deoxycytidine triphosphate (specific activities, = I O8 c p d p g ) .
A total of 0.5 ng of probe was then incubated at 4°C with 2 pL of bacterial extracts containing c-Myb or with control bacterial extracts in 20 pL containing 28 mmol/L EDTA, 15 mmoVL KCI, 6 mmol/ L MgCL, 7 mmol/L HEPES (pH 7.9 at 4 T ) , 7% glycerol, I mmol/ L dithiothreitol, and 2.5 pg poly (dI-dC). Unlabeled competitor oligonucleotides were added at 500 molar excess in competition assays and were incubated at 4°C for 15 minutes before the addition of the radioactive probe. Binding reactions were incubated for 20 minutes at 4°C. and 1.5 pL of a lox loading buffer (10 mmol/L HEPES, IO% glycerol, 0.01% bromophenol blue) was added to the reaction. A total of 12 pL of each reaction was separated by electrophoresis at 15 V/cm and 4°C on 4% to 5% polyacrylamide gels containing 0 . 4~ TBE (45 mmoVL Tris base, 45 mmol/L boric acid, 1 mmoVL EDTA) until free probe was close to the bottom of the gel, and with buffer recirculation every 15 minutes. The oligonucleotides used for EMSA were the CD1 I C promoter-derived BoxD (-94 CCTCGGAT-CAGTTG CGTACTCTGCC -70); mBoxD (5"CCTCGGATGTC-
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GACCGTACTCTGCC-3'),I2 which has mutated the putative Mybor bHLH-binding site CANNTG; 2xMyb (5"TAGAATAACGG AAGCAATAACGG AA-3'), which includes two Myb-binding sites; and m(2xMyb) (5'-TAGAATCCAGGAAGCAATCCAGG AA-3'), which has both Myb-binding sites mutated.I8 Extracts from bacteria transformed with the c-Myb cDNA in pFLAG-1 or the control empty vector (kindly provided by Drs T. Bellon and B. Calabretta; Jefferson Cancer Institute, Philadelphia, PA) were prepared by sonication of bacterial cultures grown in the presence of isopropyl P-D-thiogalactopyranoside (IPTG) for 5 hours. promoter during myeloid differentiation, U937 cells were transfected with the pCDllC361-Luc and the pSV2-neo plasmids. The G41 8-selected cell population (U937-C361) showed the same doubling time as untreated U937 cells and showed a measurable level of basal luciferase activity that increased on PMA-triggered differentiation (data not shown). Limiting dilution cloning led to the isolation of a number of clones whose levels of background luciferase activity were constant during long-term culture and ranged between 300 and 40,000 RLU/105 cells (Fig 1A) . More importantly, PMA-stimulated cell differentiation led to a 4-to 12-fold increase in the endogenous luciferase activity of the isolated clones, an induction of similar magnitude to that previously reported for the pCDllC361-Luc plasmid on transient expression in U937 cells (Fig lB) ." Hybridization with a luciferase cDNA probe showed that the copy number of the construct in the distinct U937-C361-derived clones was variable and correlated with their basal level of luciferase (Fig 1C) . Probing of a similar blot with the -361/+43 fragment from the CD1 IC promoter showed that the insertion had not affected the structure of the construct because both probes hybridized to a common set of bands (Fig 1C) . Given the colinearity of the CD 1 IC promoter and the luciferase cDNA in the transfected construct,'* the PMA-mediated increase of the luciferase level in the isolated clones reflects the differentiation-inducible activity of the CD1 IC promoter and is not caused by positional effects. The U937-C361 clone no. 2 (U937-C361#2) was chosen for further analysis based on its low but significant luciferase level under normal culture conditions (see Figs 1A and B) .
RESULTS
Stable transfection
Immunofluorescence analysis showed that, as previously described for U937 the isolated U937-C361 clones lacked Mac-l and p150,95 cell surface expression, which were detected only on PMA-stimulated differentiation (Fig  1 D) . PMA addition also promoted LFA-Mntercellular adhesion molecule-1 -mediated homotypic aggregation with similar kinetics in both U937 and U937-C361 cells (Fig 1E) . As a whole, the differentiation-associated phenotypic changes in U937-C361 cells were indistinguishable from those observed in U937 cells, indicating that the differentiation capacity of the parental cell line had not been altered by the insertion of the pCDllC361-Luc construct.
Effect of proten kinase C (PKC)-activation on the luciferase levels in U937-C361#2. Although PMA and OAG activate PKC, OAG can neither promote U937 differentiation nor induce the expression of p150,95 (Calabretta" and our unpublished results). PMA or OAG treatment of U937-C361#2 cells caused a small transient increase in luciferase activity, that returned to basal levels 6 to 9 hours after treatment (Fig 2A) , an effect also observed on addition of fresh serum or replacement of the culture medium (data not shown) and which is consistent with the presence of an AP-1 sequence within the transfected construct." However, at later time points, OAG-treated cells showed basal levels of luciferase activity, whereas the luciferase level in PMAtreated cells constantly increased up to 5 days after the phorbol-ester addition (Fig 2A) , which is in agreement with the previously described activity of the CDllc promoter in PMA-treated U937 cells?'* Therefore, as with U937 differentiation, the induction of luciferase activity in U937-C361#2 requires the continuous activation of PKC and supports the lack of differentiation-inducing ability of OAG in U937 cell^.'^ Furthermore, whereas PMA differentiation led to the appearance of CD1 IC on the cell surface, OAG had no effect on the p150,95 expression (data not shown). These results show that U937-C361#2 cells respond to PKC activators in the same manner as the parental U937 cell line and, more importantly, that the luciferase activity in U937-C361#2 cells reflects the differentiation state of the cells.
Effect of SB and GM-CSF on the luciferase activity in U937-C361 cells.
U937 cells have been previously reported to differentiate in response to SBL5 and GM-CSF?l4 and, in both cases, the expression of CD1 lc/CD18 is induced during the pro~ess.'.'~ As shown in Fig 2B, luciferase level augmented during both SB-or GM-CSF-driven differentiation, although with different kinetics (Fig 2B) , whereas agents that do not alter the differentiation state of U937 cells (y-interferon at 200 or 2,000 U/mL) left the luciferase levels unaltered (data not shown). During SB differentiation, luciferase activity increased greater than 25-fold at 24 hours, thus correlating with the appearance of CD1 IC on the cell surface (see Fig 3C) , and almost returned to basal levels after 72 hours (Fig 2B) . Following a similar kinetic profile as that used during PMA-triggered differentiation, the increase was considerably slower during GM-CSF differentiation, with a 2-to 4-fold increase between 24 and 72 hours and a maximal induction after 5 days (5-fold; see Fig 2B) , which is in agreement with the later apperance of CDllc on the membrane (Fig 3C) . Northern blot showed the presence of CD1 IC mRNA 24 hours after the addition of each differentiation agent, a time at which c-myc mRNA had been already downregulated (Fig 2C) . At all time points analyzed, PMA induced higher levels of CDllc mRNA than did SB or GM-CSF, a fact probably related to the slight c-myc mRNA reinduction observed 48 to 72 hours after GM-CSF or SB treatment (Fig 2C) . Altogether, and allowing for some quantitative differences because of posttranscriptional mechanisms, luciferase activity levels correlate with both the expression of the endogenous CDllc gene and the c-myc mRNA downregulation and, therefore, may be considered as a differentiation marker in U937-C361 cells.
For 
SB-and PMA-triggered diferentiation synergistically in-
duce the CDllc gene promoter activity and p150,95 cell su$ace expression. The distinct behavior of the CD1 I C promoter during the SB-and PMA (or GM-CSF)-triggered differentiation prompted us to analyze whether their effects were additive. As shown in Fig 3, the luciferase activity induced during the PMA-or GM-CSF-triggered differentiation was further augmented in the presence of SB, giving rise to promoter activity induction values that ranged between 50-and 100-fold. The presence of OAG during the SB-triggered differentiation had no effect on the activity of the CD1 IC promoter (data not shown), showing that transient PKC activation is not sufficient for the potentiating effect of SB. At the same time, p150,95 cell surface expression during the GM-CSF-or PMA-triggered differentiation was considerably higher in the presence of SB than was the expresion induced by either agent alone, especially at early time points. At 24 hours, the mean fluorescence intensity (MFI) for CD1 IC was 27 in the case of SB differentiation, 20 for the GM-CSF differentiation, and 49 in the presence of both agents, and the same synergistic effect was observed at 48 hours (MFI of 49, 17, and 67 with both agents; see Fig 3C) . In addition, a similar effect could be observed when SB was present during the PMA-stimulated differentiation (MFI of 49 with SB, of 79 with PMA, and of 103 with both differentiating agents; see Fig 3C) . Altogether, the above results indicate that SB-triggered differentiation induces the CD1 IC promoter activity with distinct kinetics than PMA or GM-CSF, and possibly through distinct signaling pathways.
Luciferase levels were also determined after treatment with a distinct set of differentiating The DNA topoisomerase I1 inhibitor AMSA increased luciferase activ- ity with similar kinetics and to similar levels as those for GM-CSF, which is in agreement with its ability to downregulate c-my and to induce CD1 IC expression (Fig 4 ) . ' " . " Interestingly, the effect of VP-16, which also inhibits DNA topoisomerase 11, was somewhat different as luciferase levels peaked at 72 hours and decreased afterwards (Fig 4) . On the other hand, the polar solvent DMSO" triggered luciferase levels that were maximal at 48 hours and returned to basal levels at 120 hours. Therefore, the luciferase activity in response to DMSO and SB (Fig 2B and Fig 4) returned to background levels after 120 hours, a time at which other agents showed maximal activity (GM-CSF, AMSA, PMA) or still maintained augmented levels (VP-16). As a control, 1,25 dihydroxyvitamin D3, which induces incomplete U937 differentiation,'3 failed to induce either the p150,95 expression or the activity of the CD1 I C promoter (Fig 4) . Localization of the SB and GM-CSF differentiation-responsive elements within the C D l l c promoter. Transient expression of serial deletion mutants from the -361/+43 fragment of the CD1 IC promoter showed that the differentiation-responsiveness of the CDllc promoter was retained in the -160/+43 region (Fig 5A) . Moreover, the PMA, GM-CSF, and SB differentiation-responsiveness of additional deletion mutants (pCD1 lC99-Luc, pCDl lC61-Luc, and pCDllC53-Luc) was not affected by deletion of the region contained between -160 and -99 (compare pCDllC160-Luc and pCDllC99-Luc; see Fig 5B) . However, a further deletion reduced the SB differentiation-responsiveness by a factor of 7 (70.4-v 10.6-fold induction), showing SBresponsive elements within the region -99/-61 (Fig 5B) . Removal of the consensus AP-1 sequence led to an additional threefold decrease (10.6-v 3.6-fold; see Fig 5B) , indicating that the AP-l sequence also contributes to the SBresponsiveness of the CD1 IC promoter. The remaining slight effect of SB on pCDllC53-Luc was also observed in other reporter plasmids, including the control CD 1 1 a-derived pCDllA100-Luc plasmid (Fig 5B) ,16 thus suggesting a general effect on transcription. Regarding the PMA differentiation-responsiveness of the CD1 IC promoter, it was substantially reduced by deleting the -99/-61 fragment and was completely abolished on removal of the AP-l-binding sequence (-61) 5"CTGACTCAT -3' (-53; see Fig 5B) . The response to GM-CSF was unaffected by deletion of the -991 -61 region (Fig 5B) and was only abrogated by deletion of the -61/-53 AP-l sequence (Fig 5B) , which is in agreement with the GM-CSF ability to enhance AP-l activity in U937 cells.'4 Therefore, it can be concluded that the AP-1 sequence at -61/-53 is absolutely required for the CD1 IC promoter responsiveness to PMA and GM-CSF differentiation and that it also influences its SB-inducibility, although to a lower extent.
Structural analysis on the -99/-61 region showed a consensus Myb-binding site (PyAACG/TG) at -85 (CAACTG) that is also a consensus E-box binding site for members of the basic/helix-loop-helix (b/HLH) family of transcription factors (E box = CANNTG).I2 c-Myb was shown to bind at -85 (CAACTG)(Myb-85, BoxD), because c-Myb-containing bacterial extracts, which specifically recognized the 2xMyb consensus oligo, were able to retard the BoxD double-stranded oligonucleotide (spanning from -94 to -70) but did not recognize the mBoxD probe, which lacks the Myb-binding site (Fig 6A) . Moreover, BoxD inhibited the binding of Myb to 2xMyb, and the latter abrogated the Mybcontaining retarded species on the BoxD oligonucleotide (Fig 6A) , thus clearly indicating that the CDllc proximal promoter is specifically recognized by the c-Myb transcription factor. The SB-responsiveness of the CD1 IC promoter was then analyzed by eliminating either a previously described Spl-binding site (Spl-70) which is required for optimal basal promoter activity (C. Lopez-Rodriguez and A.L. Corbi, manuscript submitted) or the E-box/Myb-binding site. Mutations that abrogated binding to Spl-70 [pCDllC160(-70MUT)-Luc] or that simultaneously disrupted the E-box and the Myb-binding site at -85 [pCDl 1C 160(-85MUT)-Luc] did not significantly inhibit the SB responsiveness of the CD 1 IC promoter in the context of the -160/+43 fragment (Fig 6B) and also left unaltered the PMA differentiation inducibility of the promoter. These results showed that the SB inducibility of the CD1 IC promoter is mediated by the -99/-61 proximal promoter region but without the involvement of the ubiquitous Spl, the tissue-restricted Myb transcription factor, or any E-box-binding b/HLH factor.
DISCUSSION
The leukocyte integrin p150,95 (CD1 lc/CD18) constitutes a marker for mononuclear phagocytes24 and is primarily expressed on cells of the myeloid although it is also found on activated B lymphocytes and is highly expressed on hairy cell leukemia ~e l l s .~~.~' We have previously shown that the promoter region of the CD1 IC gene directs the myeloid-specific expression of p150,95 and is also active in lend further support to the existence of a common set of factors mediating the inducibility of the promoter during PMA-or GM-CSF-triggered differentiation. Although deletion of the -99/-61 region only affected the PMA inducibility, elimination of the AP-I consensus sequence completely abrogated the responsiveness of the CD1 1 c promoter to both agents. This finding is in agreement with the previously reported capacity of GM-CSF to activate PKC and to enhance the AP-I activity in U937 cells." Therefore, PMA and GM-CSF may induce the CD1 I C promoter activity through a common pathway that would include activation of the AP-I complex, because the CD1 I C -611-53 sequence has been shown to be a functional AP-I site by both in vitro footprinting and EMSAs (Lopez-Cabrera et all' and C. L6pez-Rodriguez and A. L. Corbi, manuscript in preparation), and because maximal activation of AP-I in U937 cells has been shown to correlate with induction of differentiation markers.'" Because c-jios and c-jun are known to cooperate for transcriptional activation with members of the ers gene family of transcription factors,'" some of which regulate the activity of the CD1 Ib promoter,'' it is possible that such a cooperation also occurs at the CD1 IC promoter.
The CD1 I C gene promoter shows an Inr element at the major transcriptional start site." Based on physical and functional interactions between c-my and transcription factor 11-1, it has been recently proposed that c-my may repress transcription initiation from TATA-less Inr-containing genes." If this is the case, the distinct magnitude of the CD1 I C promoter induction during the PMA-and GM-CSFtriggered differentiation might arise from their opposite effects on c-my levels. PMA completely downregulates c-myc gene transcription in U937,37 whereas the downregulation of c-my by GM-CSF in U937 cells is transient (Fig 2C) and may correlate with the fact that the GM-CSF signaling pathway in other cell types leads to induction of c-my." Sitedirected mutagenesis will greatly help in the determination of the role that the Inr sequence might play in the induction of p150,95 during PMA-and GM-CSF-triggered differentiation.
A variety of low molecular weight polar solvents, such as SB or DMSO, can induce erythroid and myeloid cell differentiation,2""5.3h and SB-differentiation (and to a lower extent DMSO) produced a high and transient induction of the CD1 IC promoter activity. The exact mechanism of action of SB is unknown. However, mutation of the Spl sites within the human immunodeficiency virus-long terminal repeat (HIV-LTR) completely eliminates its SB-inducible promoter activity, and a correlation between the presence of functional Spl sites and SB-inducibility has been proposed.".'* Conversely, mutation of the Spl-70 site within the CD1 IC promoter" had no effect on the SB-inducibility, which was greatly inhibited by deletion of the -99/-61 region, therefore suggesting distinct mechanisms for the SB-responsiveness in different genes. Sequence analysis on the -99/ ~'"" we tested the effect of mutations that disrupted both the E-box and the Myb-binding site (CAACTG into GTCGAC). The lack of effect of this mutation indicates that additional proteins, distinct from Myb and b/HLH factors, mediate the SB inducibility of the CD1 I C promoter. Conversely, deletion studies suggested that the AP-I site slightly influences the SB-responsiveness, probably because of the positive effect that SB has on the expression of some members of the AP-I transcription factor comp l e~.~' The identification of the specific DNA sequence mediating the SB responsiveness of the CD1 IC promoter requires further mutagenesis studies on the identified -99/ -61 fragment.
In addition to its differentiation-inducing capacity, SB synergizes with PMA or GM-CSF in producing both a greater induction of the CD1 I C promoter activity and a higher cell surface expression of p150,95. Because PMA and GM-CSF activate PKC and stimulate the AP-I acti~ity,''."~ it is possible that the SB signaling pathway is potentiated by agents whose differentiation-inducing activity is mediated by AP-I (Fig 7) . In this sense, SB also synergizes with the antioxidant pyrrolidine dithiocarbamate, which has been recently reported to activate AP-I (Meyer et aId2 and M. Rubio and A. Corbi, unpublished results). In any event, SB appears to be potentiated only by PKC activators with differentiation-inducing ability, because the SB-stimulated CD1 I C promoter activity was not altered by the concomitant presence of OAG. A hypothetical model for the regulation of ~150.95 during myeloid differentiation, shown in Fig 7, is based on the distinct mode of action of SB and the PKC activators (GM-CSF and PMA) and their synergistic effect on the induction of the CD1 IC gene and assumes that the most relevant targets of their respective signaling pathways are the -99/-61 region (SB and PMA) and the AP-I sequence (PMA, GM-CSF, and, to a lower extent, SB).
Myeloid leukemic cells are halted at distinct stages along the differentiation pathway. The potential applicability of differentiation-triggering agents is underscored by the success of both the retinoic acid differentiation therapy in the treatment of acute promyelocytic leukemia and the clinical trials of hexamethylene bisacetamide on myelodysplastic ~yndrome.'~~'~" Our studies on the U937-C361 cells have shown the inducibility of the CD1 I C gene promoter activity during myeloid differentiation. The availability of a differentiation-responsive promoter will be also helpful for the construction of additional stable transfectants in other myeloid
